flexible-dose sublingual asenapine (10 mg twice daily on day 1; 5 or 10 mg twice daily thereafter)	placebo, or oral olanzapine 5-20 mg once daily for 3 weeks	Montgomery-Asberg Depression Rating Scale (MADRS) total score changes in patients with baseline MADRS total scores ≥20 on day on day 7 and 21	16745	17080	n patients with baseline MADRS total scores ≥20, LS mean ± SE changes from baseline in MADRS total score with asenapine were significantly greater than placebo on days 7 (-11.3 ± 1.5 vs -4.5 ± 1.6; P = 0.002) and 21 (-13.6 ± 1.6 vs-7.0 ± 1.8; P = 0.009) and were greater than olanzapine on day 7 (-11.3 ± 1.5 vs -6.9 ± 1.2; P = 0.020).
flexible-dose sublingual asenapine (10 mg twice daily on day 1; 5 or 10 mg twice daily thereafter)	placebo, or oral olanzapine 5-20 mg once daily for 3 weeks	In patients with baseline CGI-BP-D severity score ≥4, MADRS remission rates	17286	17663	In patients with baseline CGI-BP-D severity scores ≥4, LS mean ± SE changes in MADRS total score with asenapine were significantly greater than placebo on days 7 (-7.7 ± 1.1 vs -3.6 ± 1.4; P = 0.023) and 21 (-9.9 ± 1.3 vs -5.4 ± 1.6; P = 0.030), with the difference from olanzapine showing a trend towards statistical significance on day 7 (-7.7 ± 1.1 vs -5.3 ± 0.9; P = 0.088)
flexible-dose sublingual asenapine (10 mg twice daily on day 1; 5 or 10 mg twice daily thereafter)	placebo, or oral olanzapine 5-20 mg once daily for 3 weeks	In patients with a mixed episode at baseline, MADRS remission rates	22840	23138	In patients with a mixed episode at baseline, MADRS remission rates with asenapine were significantly greater than placebo on days 7 (76% vs 44%; P < 0.001) and 21 (78% vs 56%; P = 0.019); the remission rate with asenapine on day 7 was significantly greater than olanzapine (76% vs 55%; P = 0.007).
flexible-dose sublingual asenapine (10 mg twice daily on day 1; 5 or 10 mg twice daily thereafter)	placebo, or oral olanzapine 5-20 mg once daily for 3 weeks	Montgomery-Asberg Depression Rating Scale (MADRS) total score changes in patients with baseline MADRS total scores ≥20 on day on day 7 and 21	16744	17080	In patients with baseline MADRS total scores ≥20, LS mean ± SE changes from baseline in MADRS total score with asenapine were significantly greater than placebo on days 7 (-11.3 ± 1.5 vs -4.5 ± 1.6; P = 0.002) and 21 (-13.6 ± 1.6 vs-7.0 ± 1.8; P = 0.009) and were greater than olanzapine on day 7 (-11.3 ± 1.5 vs -6.9 ± 1.2; P = 0.020).
flexible-dose sublingual asenapine (10 mg twice daily on day 1; 5 or 10 mg twice daily thereafter)	placebo, or oral olanzapine 5-20 mg once daily for 3 weeks	LS mean ± SE changes in MADRS total score in patients with a mixed episode at baseline	17933	18301	In patients with a mixed episode at baseline, LS mean ± SE changes in MADRS total score were significantly greater with asenapine than placebo on days 7 (-6.7 ± 0.7 vs -3.6 ± 1.0; P = 0.011) and 21 (-8.5 ± 0.8 vs -5.8 ± 1.1; P = 0.040), with the difference from olanzapine showing a trend towards statistical significance on day 7 (-6.7 ± 0.7 vs -5.0 ± 0.7; P = 0.076)
flexible-dose sublingual asenapine (10 mg twice daily on day 1; 5 or 10 mg twice daily thereafter)	placebo, or oral olanzapine 5-20 mg once daily for 3 weeks	LS mean ± SE changes in MADRS total score in patients with a mixed episode at baseline	17933	18302	In patients with a mixed episode at baseline, LS mean ± SE changes in MADRS total score were significantly greater with asenapine than placebo on days 7 (-6.7 ± 0.7 vs -3.6 ± 1.0; P = 0.011) and 21 (-8.5 ± 0.8 vs -5.8 ± 1.1; P = 0.040), with the difference from olanzapine showing a trend towards statistical significance on day 7 (-6.7 ± 0.7 vs -5.0 ± 0.7; P = 0.076).
flexible-dose sublingual asenapine (10 mg twice daily on day 1; 5 or 10 mg twice daily thereafter)	placebo, or oral olanzapine 5-20 mg once daily for 3 weeks	MADRS remission rates in patients with baseline MADRS total scores ≥20	21705	22124	In patients with baseline MADRS total scores ≥20, MADRS remission rates (defined as MADRS total score ≤12) with asenapine were significantly greater than placebo on days 7 (57% vs 17%; P = 0.004) and 21 (70% vs 33%; P = 0.012); remission rate with asenapine on day 7 was significantly greater than olanzapine (57% vs 25%; P = 0.006) and showed a trend towards statistical significance on day 21 (70% vs 48%; P = 0.066).
flexible-dose sublingual asenapine (10 mg twice daily on day 1; 5 or 10 mg twice daily thereafter)	placebo, or oral olanzapine 5-20 mg once daily for 3 weeks	In patients with baseline CGI-BP-D severity score ≥4, MADRS remission rates	22285	22644	In patients with baseline CGI-BP-D severity score ≥4, MADRS remission rates with asenapine were significantly greater than placebo on day 7 (68% vs 35%; P = 0.014) and showed a trend towards statistical significance on day 21 (68% vs 41%; P = 0.05); the remission rate with asenapine on day 7 was significantly greater than olanzapine (68% vs 45%; P = 0.031).
